[go: up one dir, main page]

WO1999033980A3 - Membres de familles de tnf et de tnfr - Google Patents

Membres de familles de tnf et de tnfr Download PDF

Info

Publication number
WO1999033980A3
WO1999033980A3 PCT/US1998/027474 US9827474W WO9933980A3 WO 1999033980 A3 WO1999033980 A3 WO 1999033980A3 US 9827474 W US9827474 W US 9827474W WO 9933980 A3 WO9933980 A3 WO 9933980A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
members
proteins
tnfr
tnfr families
Prior art date
Application number
PCT/US1998/027474
Other languages
English (en)
Other versions
WO1999033980A2 (fr
WO1999033980A9 (fr
Inventor
Catherine Tribouley
David Pot
Altaf Kassam
George Lamson
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU20934/99A priority Critical patent/AU2093499A/en
Publication of WO1999033980A2 publication Critical patent/WO1999033980A2/fr
Publication of WO1999033980A9 publication Critical patent/WO1999033980A9/fr
Publication of WO1999033980A3 publication Critical patent/WO1999033980A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des membres de la superfamille TNF et TNFR de protéines qui ont été identifiés. Ces protéines vont servir de cibles pour une intervention ou mimétique thérapeutique. Les protéines TNF-L et TNFR-L peuvent servir à induire la mort des cellules et/ou la prolifération de cellules. Les membres de ces superfamilles sont associés à un large éventail de processus morbides, raison pour laquelle ils sont pris comme régulateurs biologiques et physiologiques centraux.
PCT/US1998/027474 1997-12-30 1998-12-22 Membres de familles de tnf et de tnfr WO1999033980A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20934/99A AU2093499A (en) 1997-12-30 1998-12-22 Members of tnf and tnfr families

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6895997P 1997-12-30 1997-12-30
US60/068,959 1997-12-30
US21227098A 1998-12-16 1998-12-16
US09/212,270 1998-12-16

Publications (3)

Publication Number Publication Date
WO1999033980A2 WO1999033980A2 (fr) 1999-07-08
WO1999033980A9 WO1999033980A9 (fr) 1999-10-14
WO1999033980A3 true WO1999033980A3 (fr) 1999-11-18

Family

ID=26749548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027474 WO1999033980A2 (fr) 1997-12-30 1998-12-22 Membres de familles de tnf et de tnfr

Country Status (2)

Country Link
AU (1) AU2093499A (fr)
WO (1) WO1999033980A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CN1247567A (zh) 1997-01-14 2000-03-15 人体基因组科学有限公司 肿瘤坏死因子受体6α和6β
ATE360032T1 (de) 1997-09-12 2007-05-15 Biogen Idec Inc Cystein-reiche rezeptoren-train
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000043032A2 (fr) 1999-01-25 2000-07-27 Biogen, Inc. Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
EP1860190A3 (fr) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Variantes d'épissage de neutrokine-alpha, et neutrokine-alpha
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
BR0013391A (pt) 1999-08-17 2002-07-09 Biogen Inc Uso do receptor baff (bcma) como um agente imunoregulador
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
CA2408617A1 (fr) 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
WO2002009755A2 (fr) 2000-07-27 2002-02-07 Genentech, Inc. Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
WO2002094192A2 (fr) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Anticorps contre le facteur de necrose tumorale delta (april)
ES2328234T3 (es) 2001-07-03 2009-11-11 Genentech, Inc. Anticuerpos dr4 humanos y utilizaciones de los mismos.
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
CA2526402A1 (fr) 2003-06-05 2005-01-20 Genentech, Inc. Antagonistes de blys et leurs utilisations
JP2008505607A (ja) 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
KR20070100228A (ko) 2004-10-05 2007-10-10 제넨테크, 인크. 혈관염의 치료 방법
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2833852C (fr) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
CA2663599A1 (fr) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Procede de traitement du cancer presentant des mutations egfr
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (fr) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Facteurs de necrose tumorale delta et epsilon chez l'homme
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
WO1998055621A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (fr) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Facteurs de necrose tumorale delta et epsilon chez l'homme
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
WO1998055621A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGGARWAL B.B. AND NATARAJAN K.: "Tumor necrosis factor: developments during the last decade", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01) - June 1996 (1996-06-01), pages 93 - 124, XP002094503 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002101204, Database accession no. AA682496 *
GRUSS H.-J. AND DOWER S.K.: "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas", BLOOD, vol. 85, no. 12, 15 June 1995 (1995-06-15), pages 3378 - 3404, XP002094502 *
GRUSS H.-J.: "Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, vol. 26, no. 3, 1996, pages 143 - 159, XP002094504 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Also Published As

Publication number Publication date
WO1999033980A2 (fr) 1999-07-08
WO1999033980A9 (fr) 1999-10-14
AU2093499A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
WO1999033980A3 (fr) Membres de familles de tnf et de tnfr
WO2000060079A3 (fr) Nouveaux membres des familles tnf et tnfr
Scanlon et al. Cisplatin resistance in human cancers
Bandeira-Melo et al. Cutting edge: eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils
Marshall Less hype, more biology needed for gene therapy
CA2005016A1 (fr) Fragment d'adn contenant un promoteur de site de l'elongation de la chaine de polypeptide humaine de facteur-1.alpha. et plamisde d'expression contenant ce fragment d'adn
CA2228635A1 (fr) Famille de genes mammaliens de proteines inhibant l'apoptose (iap), amorces, sondes et procedes de detection
GR3015015T3 (en) Leukocyte poor red blood cell storage system.
ATE397665T1 (de) Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
AU1265097A (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
Bloomfield et al. Enhanced release of inflammatory mediators from lithium‐stimulated neutrophils in psoriasis
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
Howell mtDNA recombination: what do in vitro data mean?
EP0525917A3 (fr) Corrections des désordres métaboliques associés aux cycles viraux et aux cellules tumorales incontrôlées par un DS-ARN
AU3584993A (en) Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
Copeland et al. Regional localization of three convertases, PC1 (Nec-1), PC2 (Nec-2), and furin (Fur), on mouse chromosomes
Moore et al. Malic dehydrogenases in sea urchin eggs
Konstantinović et al. Nuclear matrix from resting and concanavalin A-stimulated human lymphocytes
Pool et al. Zygote intrafallopian transfer with" donor rescue": a new option for severe male factor infertility
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine
ATE118819T1 (de) Dna moleküle, welche plazentales rinder-lactogen- peptid und das pre-peptid kodieren und genetisch transformierte zellen, die diese moleküle enthalten.
Guglielmi et al. Prevalence of monoclonal Ig with λ light chains in chronic myelocytic leukaemia
Katakura et al. The Presence of Protein Disulfide Isomerase in the Yeast Saccharomyces cerevisiae
DE69017870D1 (de) Pharmazeutische Zubereitungen, die 3-Oxygermylpropionsäurepolymere enthalten zur Hemmung von Zelldegeneration.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase